2023 Consensus Statement – Adjuvant therapy for renal cell carcinoma

Eligible patients should be informed about adjuvant ICI therapy and offered referral to medical oncology to discuss the benefits and risks in a shared decision-making approach.

Several recent randomized trials evaluated the impact of adjuvant immune checkpoint inhibitor (ICI)-based therapy on post surgical outcomes in renal cell carcinoma (RCC), with disparate results. The objective of the consensus statement is to provide data-driven guidance regarding the use of ICIs after complete resection of clear-cell RCC in a Canadian context.


See Consensus Statement


Kidney Cancer Canada